Cassava Sciences Inc (SAVA)

[CogDiss 1188X]

Cassava getting some love from Fortune.

Cassava Sciences—a drugmaker with no products on the market—is currently 2021’s best biotech performer

https://fortune.com/2021/06/08/cassava-sciences-alzheimers-drug-share-price-biogen/

The fundamentals of our story are in place, which is this is the first drug—to our knowledge—that can restore cognition,” Cassava’s founder and chief executive Remi Barbier said in an interview.

Despite a stock rally that makes his 5% stake—including options—worth more than $100 million, Barbier says he’s not selling. “I know the science, I know the data, I know the disease and this stuff looks promising and I’m putting my money where my mouth is.”

One of the things that convinced me to start buying January of 2020 was that multiple insiders bought heavily in December of 2019. Looks like they’re still convinced they’re going to be billionaires.

Next card, perhaps the key one, will flip in July with 9 month interim results. Alzheimer’s patients apparently do not get better for 9 months on “placebos.” A positive result at that point would remove much of the doubt due to open label, etc.